Since its inception, SCYNEXIS has developed an exciting pipeline of technologies, including three platforms centered on anti-fungal, anti-viral, and anti-inflammatory treatments. SCYNEXIS is building proprietary pipelines of drugs that it will develop in partnership.
SCY-078, the first compound from the Enfumafungin anti-fungal platform, is in Phase 2 studies for invasive fungal infections (IFI).
SCY-635, the first compound from the cyclophilin inhibitors anti-viral platform, has just completed Phase 2a clinical studies for the treatment of Hepatitis C (HCV).
SCY-641, the first compound from the calcineurin inhibitors platform, is in preclinical studies for human health and is entering Phase 3 clinical studies for animal health. This compound was recently licensed to Dechra Pharmaceuticals PLC, a UK-listed international veterinary pharmaceutical business for development and commercialization for the treatment of canine keratoconjunctivitis sicca (KCS).
Additionally, SCYNEXIS has two other compounds for animal health in late clinical development with Merial, a division of Sanofi.